Summary

Persistence Market Research has recently released a comprehensive report on the global Orally Disintegrating Tablet (ODT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Orally Disintegrating Tablet Market Size (2025E): US$ 25,082.1 Mn
• Projected Market Value (2032F): US$ 48,186.8 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 8.5%

Orally Disintegrating Tablet Market – Report Scope:

The Orally Disintegrating Tablet (ODT) market comprises pharmaceutical formulations that dissolve or disintegrate rapidly in the mouth without the need for water. These tablets are widely used across various therapeutic areas due to their ease of administration, improved patient compliance, and suitability for pediatric and geriatric populations. Rising demand for innovative drug delivery systems, coupled with growing prevalence of chronic and neurological disorders, is accelerating the adoption of ODTs. Pharmaceutical companies are investing in advanced formulation technologies and targeting unmet patient needs to expand their portfolios and capture greater market share.

Market Growth Drivers:

The global ODT market is experiencing steady growth due to several favorable factors. The increasing incidence of neurological and psychiatric conditions, such as epilepsy, Parkinson’s disease, and schizophrenia, is contributing significantly to demand, as ODTs offer a more convenient dosage form for patients who have difficulty swallowing. Moreover, the growing pediatric and geriatric population—two key demographics for whom traditional tablets pose challenges—further drives the adoption of ODTs. Additionally, the rise in demand for faster-acting formulations in therapeutic areas like pain relief and allergies has encouraged pharmaceutical firms to develop ODT versions of existing drugs. Technological advancements in taste-masking and rapid disintegration are also facilitating the development of more palatable and effective ODTs, enhancing patient adherence and therapeutic outcomes.

Market Restraints:

Despite strong growth prospects, the ODT market faces several limitations. One of the key challenges is the complexity and cost of manufacturing ODTs compared to conventional tablets. These formulations often require specialized equipment and technologies such as lyophilization or direct compression, which can be capital-intensive. Moreover, not all drugs are suitable for ODT formulations, especially those with high dosage requirements or unpleasant taste profiles that are difficult to mask effectively. Regulatory hurdles and stability concerns, particularly with moisture-sensitive compounds, can also delay product approvals and time-to-market, thereby restraining growth.

Market Opportunities:

The ODT market presents numerous opportunities for growth and innovation. Increasing focus on patient-centric drug design and the growing popularity of self-administered medication provide a strong foundation for market expansion. Pharmaceutical companies are exploring novel APIs and fixed-dose combinations suitable for ODTs to differentiate their product offerings and extend patent life. Expanding access to healthcare in emerging markets across Asia-Pacific, Latin America, and the Middle East and Africa presents untapped potential, particularly through online and retail pharmacy channels. Furthermore, strategic collaborations between drug developers and contract manufacturing organizations (CMOs) can facilitate cost-effective production and faster commercialization of new ODT products.

Key Questions Answered in the Report:

• What are the primary factors driving the global ODT market’s growth?
• Which regions and therapeutic segments are witnessing the highest demand for ODTs?
• How are innovations in formulation technology influencing market dynamics?
• Who are the key players in the ODT market, and what strategies are they adopting to remain competitive?
• What are the emerging trends and future projections for the global ODT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global ODT market, such as Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., and Pfizer Inc., are focusing on formulation innovation, lifecycle management of blockbuster drugs, and expanding their presence in high-growth regions. These players are also investing in taste-masking technologies, disintegration enhancers, and fast-melt systems to improve patient experience and treatment outcomes. Strategic partnerships, mergers and acquisitions, and co-development agreements are common approaches to gain competitive advantage. In addition, the emergence of digital pharmacies and evolving consumer preferences toward convenience-based healthcare solutions are shaping new business models in the ODT landscape.

Companies Covered in This Report:

• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• AstraZeneca
• Mylan N.V.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Bausch Health
• GlaxoSmithKline plc.
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Eli Lilly and Company

Orally Disintegrating Tablet Market Segmentation:

By Drug Class:

• Anti-Psychotics
• Anti-Epileptics
• CNS Stimulants
• Anxiolytics
• Anti-Parkinsonian Drugs
• Anti-Hypertensives
• NSAIDs
• Anti-Allergy Drugs
• Proton Pump Inhibitors
• Others

By Disease Indication:

• CNS Diseases
• GI Diseases
• CVS Disorders
• Allergy
• Others

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Orally Disintegrating Tablet Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Orally Disintegrating Tablet Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
4.3. Global Orally Disintegrating Tablet Market Outlook: Drug Class
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
4.3.3.1. Anti-Psychotics
4.3.3.2. Anti-Epileptics
4.3.3.3. CNS Stimulants
4.3.3.4. Anxiolytics
4.3.3.5. Anti-Parkinsonian Drugs
4.3.3.6. Anti-Hypertensives
4.3.3.7. NSAIDS
4.3.3.8. Anti-Allergy Drugs
4.3.3.9. Proton Pump Inhibitors
4.3.3.10. Others
4.3.4. Market Attractiveness Analysis: Drug Class
4.4. Global Orally Disintegrating Tablet Market Outlook: Disease Indication
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2019-2024
4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
4.4.3.1. CNS Diseases
4.4.3.2. GI Diseases
4.4.3.3. CVS Disorders
4.4.3.4. Allergy
4.4.3.5. Others
4.4.4. Market Attractiveness Analysis: Disease Indication
4.5. Global Orally Disintegrating Tablet Market Outlook: Distribution Channel
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
4.5.3.1. Hospital Pharmacies
4.5.3.2. Retail Pharmacies
4.5.3.3. Drug Stores
4.5.3.4. Online Pharmacies
4.5.4. Market Attractiveness Analysis: Distribution Channel
5. Global Orally Disintegrating Tablet Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Orally Disintegrating Tablet Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Drug Class
6.2.3. By Disease Indication
6.2.4. By Distribution Channel
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
6.4.1. Anti-Psychotics
6.4.2. Anti-Epileptics
6.4.3. CNS Stimulants
6.4.4. Anxiolytics
6.4.5. Anti-Parkinsonian Drugs
6.4.6. Anti-Hypertensives
6.4.7. NSAIDS
6.4.8. Anti-Allergy Drugs
6.4.9. Proton Pump Inhibitors
6.4.10. Others
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
6.5.1. CNS Diseases
6.5.2. GI Diseases
6.5.3. CVS Disorders
6.5.4. Allergy
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Drug Stores
6.6.4. Online Pharmacies
6.7. Market Attractiveness Analysis
7. Europe Orally Disintegrating Tablet Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Drug Class
7.2.3. By Disease Indication
7.2.4. By Distribution Channel
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
7.4.1. Anti-Psychotics
7.4.2. Anti-Epileptics
7.4.3. CNS Stimulants
7.4.4. Anxiolytics
7.4.5. Anti-Parkinsonian Drugs
7.4.6. Anti-Hypertensives
7.4.7. NSAIDS
7.4.8. Anti-Allergy Drugs
7.4.9. Proton Pump Inhibitors
7.4.10. Others
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
7.5.1. CNS Diseases
7.5.2. GI Diseases
7.5.3. CVS Disorders
7.5.4. Allergy
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Drug Stores
7.6.4. Online Pharmacies
7.7. Market Attractiveness Analysis
8. East Asia Orally Disintegrating Tablet Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Drug Class
8.2.3. By Disease Indication
8.2.4. By Distribution Channel
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
8.4.1. Anti-Psychotics
8.4.2. Anti-Epileptics
8.4.3. CNS Stimulants
8.4.4. Anxiolytics
8.4.5. Anti-Parkinsonian Drugs
8.4.6. Anti-Hypertensives
8.4.7. NSAIDS
8.4.8. Anti-Allergy Drugs
8.4.9. Proton Pump Inhibitors
8.4.10. Others
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
8.5.1. CNS Diseases
8.5.2. GI Diseases
8.5.3. CVS Disorders
8.5.4. Allergy
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Drug Stores
8.6.4. Online Pharmacies
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Orally Disintegrating Tablet Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Drug Class
9.2.3. By Disease Indication
9.2.4. By Distribution Channel
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
9.4.1. Anti-Psychotics
9.4.2. Anti-Epileptics
9.4.3. CNS Stimulants
9.4.4. Anxiolytics
9.4.5. Anti-Parkinsonian Drugs
9.4.6. Anti-Hypertensives
9.4.7. NSAIDS
9.4.8. Anti-Allergy Drugs
9.4.9. Proton Pump Inhibitors
9.4.10. Others
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
9.5.1. CNS Diseases
9.5.2. GI Diseases
9.5.3. CVS Disorders
9.5.4. Allergy
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Drug Stores
9.6.4. Online Pharmacies
9.7. Market Attractiveness Analysis
10. Latin America Orally Disintegrating Tablet Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Drug Class
10.2.3. By Disease Indication
10.2.4. By Distribution Channel
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
10.4.1. Anti-Psychotics
10.4.2. Anti-Epileptics
10.4.3. CNS Stimulants
10.4.4. Anxiolytics
10.4.5. Anti-Parkinsonian Drugs
10.4.6. Anti-Hypertensives
10.4.7. NSAIDS
10.4.8. Anti-Allergy Drugs
10.4.9. Proton Pump Inhibitors
10.4.10. Others
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
10.5.1. CNS Diseases
10.5.2. GI Diseases
10.5.3. CVS Disorders
10.5.4. Allergy
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Drug Stores
10.6.4. Online Pharmacies
10.7. Market Attractiveness Analysis
11. Middle East & Africa Orally Disintegrating Tablet Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Drug Class
11.2.3. By Disease Indication
11.2.4. By Distribution Channel
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
11.4.1. Anti-Psychotics
11.4.2. Anti-Epileptics
11.4.3. CNS Stimulants
11.4.4. Anxiolytics
11.4.5. Anti-Parkinsonian Drugs
11.4.6. Anti-Hypertensives
11.4.7. NSAIDS
11.4.8. Anti-Allergy Drugs
11.4.9. Proton Pump Inhibitors
11.4.10. Others
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
11.5.1. CNS Diseases
11.5.2. GI Diseases
11.5.3. CVS Disorders
11.5.4. Allergy
11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
11.6.1. Hospital Pharmacies
11.6.2. Retail Pharmacies
11.6.3. Drug Stores
11.6.4. Online Pharmacies
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Teva Pharmaceutical Industries Ltd.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Novartis AG
12.3.3. AstraZeneca
12.3.4. Mylan N.V.
12.3.5. Pfizer Inc.
12.3.6. Johnson & Johnson Services, Inc.
12.3.7. F. Hoffmann-La Roche Ltd.
12.3.8. Merck & Co., Inc.
12.3.9. Bausch Health
12.3.10. GlaxoSmithKline plc.
12.3.11. Sun Pharmaceutical Industries Ltd.
12.3.12. Bayer AG
12.3.13. Eli Lily and Company
12.3.14. Dr. Reddy’s Laboratories Ltd.
12.3.15. Takeda Pharmaceutical Company Limited
12.3.16. Catalent Pharma Solutions
12.3.17. Neos Therapeutics
12.3.18. Eisai Co.
12.3.19. Zydus Lifesciences
12.3.20. Aurobindo Pharma
12.3.21. Torrent Pharmaceuticals
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations